Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00104377 · ClinicalTrials.gov registry record · Phase 2
Induction of Immunogenicity With Different Doses of Grass MATA in Subjects Allergic to Grass and Rye Pollen
A Phase 2 study of Type I Hypersensitivity, sponsored by Allergy Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 70
- Enrollment target
- 11
- Study locations
NCT00104377 is a Phase 2 study of Type I Hypersensitivity that has completed, run by Allergy Therapeutics. The registered enrollment target is 70 participants. The trial reports 11 study locations across 9 states.
The verdict
NCT00104377, a Phase 2 study of Type I Hypersensitivity, has completed, sponsored by Allergy Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 70 participants
- Enrollment target
- 11
- Study locations
Study Summary
Grass MATA (modified pollen allergen tyrosine adsorbate) has been developed to provide pre-seasonal specific immunotherapy for patients with hypersensitivity to grass and rye pollen. Different doses of Grass MATA will be administered and immunological changes following this treatment will be assessed.
Conditions Studied
Interventions
- BIOLOGICAL Grass MATA MPL
Study Locations (11)
Oregon
- Clinical Research Institute of Southern Oregon, PC - Medford
- Allergy Associates Research Center - Portland
Pennsylvania
- Allergy and Clinical Immunology Associates - Pittsburgh
- Asthma and Allergy Research Associates - Upland
Kansas
- College Park Family Care Center Multi-Specialty Clinical Research - Overland Park
Massachusetts
- Northeast Medical Research Associates - North Dartmouth
Missouri
- Midwest Clinical research, LLC - St Louis
Nebraska
- Allergy, Asthma, and Immunology Assoc. PC - Lincoln
New Jersey
- Asthma, Sinus, and Allergy Centers, LLC - Tinton Falls
Ohio
- Bernstein Clinical Research Center, LLC - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2005-03 |
| Est. Completion | 2005-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00104377
The ClinicalTrials.gov registry entry for NCT00104377 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergy Therapeutics, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Type I Hypersensitivity appearing as the primary indexed condition, and to 1 intervention - of which Grass MATA MPL is the first listed.
NCT00104377 reports 11 study locations spanning 9 distinct geographic areas - top geographies include Oregon, Pennsylvania, Kansas.
Frequently Asked Questions
What is clinical trial NCT00104377 about?
NCT00104377 is a clinical study titled "Induction of Immunogenicity With Different Doses of Grass MATA in Subjects Allergic to Grass and Rye Pollen". Grass MATA (modified pollen allergen tyrosine adsorbate) has been developed to provide pre-seasonal specific immunotherapy for patients with hypersensitivity to grass and rye pollen. Different doses of Grass MATA will be administered and immunological changes following this treatment will be assesse...
What is the current status of trial NCT00104377?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 70 participants. The study started on 2005-03. Estimated completion is 2005-11.
What conditions does trial NCT00104377 study?
This clinical trial studies the following conditions: Type I Hypersensitivity.
What interventions are being tested in trial NCT00104377?
The interventions under investigation include: Grass MATA MPL (BIOLOGICAL).
Who is sponsoring clinical trial NCT00104377?
This trial is sponsored by Allergy Therapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00104377 being conducted?
This trial has 11 study locations across Kansas, Massachusetts, Missouri, Nebraska, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type I Hypersensitivity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.